Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9409890-B2
Application number	US-201314082472-A
Country	US
Kind code	B2
Filing date	Nov 18, 2013
Priority date	Nov 16, 2010
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.

First claim

What is claimed:

1. A method of treating multiple myeloma in a subject comprising administering to the subject a compound of formula VI:

or a pharmaceutically acceptable salt thereof,

wherein,
R x and R y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, oxazolidinyl, or imidazolidinyl;
each R A is independently alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, arylalkyl, heteroarylalkyl, haloalkyl, haloalkoxy, halo, OH, —NO 2 , —CN, or —NH 2 ; and
m is 0, 1, or 2.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the compound of formula VI is selected from the following:

and pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the compound of formula VI is selected from the following:

and pharmaceutically acceptable salts thereof.

5. The method of claim 1 , wherein the compound of formula VI is:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound of formula VI is:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound of formula VI is:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound of formula VI is selected from the following:

and pharmaceutically acceptable salts thereof.

Assignees

• Acetylon Pharmaceuticals Inc
• Acetylon Pharamceuticals Inc

Inventors

• Van Duzer John H
• Mazitschek Ralph
• Ding Yanbing
• Yu Nan
• Cao Yun
• Liu Yong

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/04

  Chelating agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title